Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the results of a study that compared the respective toxicities and quality of life outcomes associated with standard radiation and pelvic intensity-modulated radiation therapy for patients with various gynecologic malignancies.
Hagop M. Kantarjian, MD, professor, department of Leukemia, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolving and future role of chemotherapy in the treatment paradigm of acute lymphoblastic leukemia (ALL).
There are a wide variety of novel agents currently being investigated in the neoadjuvant setting for patients with HER2-positive breast cancer.
Madeleine Duvic, MD, professor of Medicine and Dermatology, Blanche Bender Professorship in Cancer Research, director of the Research Fellowship Program, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of classifying T-cell lymphomas and new targets in development. Duvic shared this insight during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.
Enrolling clinical trials can be a long process, especially in rare diseases with limited patient populations. This is a particularly significant issue for patients with anaplastic thyroid cancer, an extremely rare and aggressive disease.
Guillermo Garcia-Manero, MD, professor of Medicine, chief, Section of Myelodysplastic Syndromes, in the Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential of curing patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Garcia-Manero explained this reasoning in an interview during the 2016 OncLive State of the Science Summit on Treatment of Hematologic Malignancies.
When envisioning the future treatment paradigms for myelodysplastic syndromes and acute myeloid leukemia, researchers predict that hypomethylating agents, immunotherapies, and multikinase and BCL-2 inhibitors are just a few examples of what the field can expect in the coming years.
Both myelofibrosis and polycythemia vera are myeloproliferative neoplasms with very specific characteristics and treatment strategies.
While immunotherapy is currently only beneficial in select cancers, it is possible for this type of treatment to eventually work for all patients.
William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the management of patients with chronic lymphocytic leukemia (CLL) in the firstline setting.
Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent treatment advances and emerging subsets in acute lymphoblastic leukemia (ALL).
Loretta J. Nastoupil, MD, an assistant professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, discusses what treatment approaches she sees on the horizon in the landscape of large cell lymphoma. Nastoupil shared this insight in an interview during the 2016 OncLive State of the Science on Hematologic Malignancies.
Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, Anderson Clinical Faculty Chair for Cancer Treatment and Research, The University of Texas MD Anderson Cancer Center, discusses how pathologists maximize outcomes with limited tissue in patients with lung cancer.
James C. Yao, MD, discusses developments in the field of neuroendocrine tumors.
Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how the results of the phase III FIRE-3 and 80405 studies will impact treatment of patients with metastatic colorectal cancer.
Jan S. Lewin, PhD, professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the impact of lymphedema in patients with head and neck cancer.
Michael J. Overman, MD, discusses the findings of the phase II CheckMate-142 study, which examined nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with high microsatellite instability colorectal cancer.
Patients with nonfunctioning neuroendocrine tumors of lung or gastrointestinal origin continued to live longer when treated with the mammalian target of rapamycin inhibitor everolimus (Afinitor) than with placebo.
Precancerous colon polyps exhibit many of the same driver mutations that fuel the development of colorectal cancer.
William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunotherapy agents being explored in patients with chronic lymphocytic leukemia (CLL).
Researchers are exploring the safety and efficacy of the novel CDK 4/6 inhibitor ribociclib (LEE011) in the phase III MONALEESA- 7 trial.
Jorge E. Cortes, MD, deputy department chair, professor of Medicine and Internist, chair, AML Sections, D. B. Lane Cancer Research Distinguished Professor for Leukemia Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action for BP-100.01.
Padmanee Sharma, MD, PhD, professor of Immunology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses PD-L1 as a predictive biomarker for immunotherapy in patients with bladder cancer.
David M. Gershenson, MD, professor, Obstetrics, Gynecology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, discusses the evolution of targeted therapies for patients with rare gynecologic malignancies.
Cathy Eng, MD, FACP, professor, director, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Network Clinical Research, associate medical director, Colorectal Center, University of Texas MD Anderson Cancer Center, discusses emerging agents for the treatment of patients with anal cancer.
Contemporary efforts toward defining molecular subsets of colorectal cancer can potentially aid our ability to refine therapy and improve outcomes for patients with colorectal cancer.
James Allison, chair of Immunology at the University of Texas MD Anderson Cancer Center, discusses promising data regarding the use of immunotherapies in melanoma. Allison is particularly excited about a trial, presented at the Society of Melanoma Research Congress, which looked at the combination of PD-L1 inhibitors with a BRAF-targeted agent.
James Allison, PhD, discusses the rapidly expanding field of immunotherapy in melanoma.
William G. Wierda, MD, PhD, gives a better understanding of the changing landscape of chronic lymphocytic leukemia and how treatment options vary among different patient subtypes.
Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.
